RNAC SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 30, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 5, 2026

8-K

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Sep 29, 2026

8-K

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Aug 6, 2026

8-K

Cartesian Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 17, 2026

8-K

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform

Jun 9, 2026

8-K

Cartesian Therapeutics Secures up to $150 Million in Non-Dilutive Financing and Updates Clinical Pipeline Timelines

May 26, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B7

Form 424B7 - Prospectus [Rule 424(b)(7)]

Jan 8, 2025

424B7

Form 424B7 - Prospectus [Rule 424(b)(7)]

Jan 8, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jan 8, 2025

424B7

SHARE RESALE REGISTRATION | Shares amount: 6,501,150

Oct 1, 2024

424B5

Apr 6, 2022

424B5

ATM | Offering amount: $75,000,000

Oct 25, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 30, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Jan 10, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Jan 10, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

Dec 13, 2024

S-3

Form S-3 - Registration statement under Securities Act of 1933

Dec 13, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Aug 16, 2024

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Aug 2, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

BARCLAYS PLC (Filed by)

Nov 6, 2026

SCHEDULE 13G

BARCLAYS PLC (Filed by)

Aug 13, 2026

SCHEDULE 13G/A

JPMORGAN CHASE & CO (Filed by)

Jul 22, 2026

144

Form 144 - Report of proposed sale of securities

Jun 9, 2026

144

Form 144 - Report of proposed sale of securities

Jun 2, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

May 6, 2026

Other

TYPE

HEADLINE

FILED AT

Cartesian Therapeutics, Inc. RNAC · SEC Filings